Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above 200-Day Moving Average – Here’s Why

Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.29 and traded as high as $5.30. Cumberland Pharmaceuticals shares last traded at $5.17, with a volume of 124,744 shares changing hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 6th.

Cumberland Pharmaceuticals Trading Up 3.6 %

The company has a quick ratio of 0.99, a current ratio of 1.13 and a debt-to-equity ratio of 0.41. The company’s 50-day moving average is $3.88 and its 200 day moving average is $2.29. The company has a market cap of $72.60 million, a price-to-earnings ratio of -6.71 and a beta of -0.19.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its earnings results on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter. The business had revenue of $10.44 million for the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%.

Institutional Trading of Cumberland Pharmaceuticals

An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Two Sigma Investments LP boosted its stake in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) by 94.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 37,649 shares of the specialty pharmaceutical company’s stock after acquiring an additional 18,271 shares during the period. Two Sigma Investments LP owned about 0.27% of Cumberland Pharmaceuticals worth $89,000 at the end of the most recent quarter. 15.51% of the stock is currently owned by hedge funds and other institutional investors.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.